Şener YZ, Şener S. Treatment of immunoglobulin A nephropathy: Current perspective and future prospects. World J Clin Cases 2025; 13(19): 101196 [DOI: 10.12998/wjcc.v13.i19.101196]
Corresponding Author of This Article
Yusuf Ziya Şener, MD, MSc, Research Assistant, Department of Cardiology, Thoraxcentrum, Erasmus MC, Rotterdam 3015 GD, Netherlands. yzsener@yahoo.com.tr
Research Domain of This Article
Urology & Nephrology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Treatment of immunoglobulin A nephropathy: Current perspective and future prospects
Yusuf Ziya Şener, Seher Şener
Yusuf Ziya Şener, Department of Cardiology, Thoraxcentrum, Erasmus MC, Rotterdam 3015 GD, Netherlands
Seher Şener, Department of Pediatric Rheumatology, Erasmus MC, Rotterdam 3015 GD, Netherlands
Author contributions: Şener YZ contributed to the design, concept and writing of the manuscript; Şener S contributed to the design, literature review and manuscript editing; all of the authors read and approved the final version of the manuscript to be published.
Conflict-of-interest statement: The authors declare no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yusuf Ziya Şener, MD, MSc, Research Assistant, Department of Cardiology, Thoraxcentrum, Erasmus MC, Rotterdam 3015 GD, Netherlands. yzsener@yahoo.com.tr
Received: September 6, 2024 Revised: February 9, 2025 Accepted: February 17, 2025 Published online: July 6, 2025 Processing time: 193 Days and 8.4 Hours
Core Tip
Core Tip: Immunoglobulin A nephropathy represents the most prevalent form of primary glomerulonephritis, with the potential for progression to end-stage renal disease. Lifestyle modifications, dietary alterations and anti-proteinuric pharmacological agents have been demonstrated to induce clinical remission in most cases. However, some cases do not respond to supportive therapy. Short term use of corticosteroids should be considered in unresponsive cases. However, novel therapeutic strategies are required for patients with steroid-refractory disease. B-cell lineage depletion therapies and complement system inhibitors represent promising avenues for future research and may be considered in cases of persistent disease despite guideline-directed medical treatment.
